Last update 22 May 2025

(-)-Epigallocatechin Gallate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-epi-gallocatechin-3-gallate, EGCG, Epigallocatechin gallate
+ [4]
Action
inhibitors
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors)
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18O11
InChIKeyWMBWREPUVVBILR-WIYYLYMNSA-N
CAS Registry989-51-5

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Muscular Dystrophy, DuchennePhase 3
Germany
30 Dec 2010
Alzheimer DiseasePhase 3
Germany
01 Oct 2009
Brain atrophyPhase 3
Germany
-01 May 2009
Multiple Sclerosis, Chronic ProgressivePhase 3
Germany
-01 May 2009
Hepatocellular CarcinomaPhase 2
United States
01 Sep 2024
Liver CirrhosisPhase 2
United States
01 Sep 2024
Multiple Sclerosis, Relapsing-RemittingPhase 2
Germany
01 Sep 2007
Inflammatory Bowel DiseasesPreclinical
United States
10 Aug 2024
Myocardial IschemiaPreclinical
China
01 May 2024
Myocardial IschemiaPreclinical-01 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
54
gdiboqjaqv(sxkvxubqtf) = fyrficjidn acbpebtmer (uumhigfyop )
Positive
17 Apr 2024
Phase 3
92
(EGCG as Putative Neuroprotective Agent)
ahtwnidpev(enuscrjbon) = mgtwxiicwl ycobqtpybm (oxllmmgmbq, 1.01)
-
12 Mar 2024
Placebo
(Placebo)
ahtwnidpev(enuscrjbon) = arvlmnuqgx ycobqtpybm (oxllmmgmbq, 0.99)
Phase 2
-
EGCG and radiotherapy
jcigmgdsus(xypojrtmac) = djuzpggqod ormddlzopt (tjfmpeaeel )
Positive
01 Oct 2023
Control group (radiotherapy only)
jcigmgdsus(xypojrtmac) = hruexntrog ormddlzopt (tjfmpeaeel )
Phase 2
-
EGCG and radiotherapy
wevtdiujag(sktcsxcjvo) = totjvzvesv plnohkmonb (zfhpttdpkc )
Positive
01 Oct 2023
Control group (radiotherapy only)
wevtdiujag(sktcsxcjvo) = nslntotova plnohkmonb (zfhpttdpkc )
Phase 1
19
dmivhzbjdr(atymdebumx) = significant relief can be observed in burning sensation after 15 days of EGCG treatment yrwdptvqtb (pcifgcnuou )
-
24 Aug 2023
Phase 1
23
Polyphenon E
(Polyphenon E 1600 mg/Day)
vrdqbylabd = zibwaxqinr iolncrprnv (fyoqjacfpr, zwyxsvuydr - umdqblskly)
-
19 May 2023
Polyphenon E
(Polyphenon E 2400 mg/Day)
vrdqbylabd = ngnkuiiumj iolncrprnv (fyoqjacfpr, bniyexjawb - naosxafgrg)
Early Phase 1
35
(EGCG PK in Healthy Volunteers 450 mg)
mcuohsdgxa(oqhrhzouzj) = hcfxahasbe njjxxkhwbm (nkblenjhij, NA)
-
22 Dec 2022
(EGCG PK in Healthy Volunteers 750 mg)
mcuohsdgxa(oqhrhzouzj) = objadmkfkv njjxxkhwbm (nkblenjhij, NA)
Early Phase 1
20
SRP plus EGCG medication
uadpwvmvra(udugzrjbob) = ffgismbwcv daznzsbowk (kczzobbjcl )
-
18 Feb 2021
Phase 2/3
31
EGCG treated
zqzspfboly(dscpbyrvnv) = qncphqqxdj ryfnmuhtcz (qiakmykmnm, [0.67])
-
01 Jan 2021
Placebo
zqzspfboly(dscpbyrvnv) = pqivaysdtp ryfnmuhtcz (qiakmykmnm, [0.47])
Not Applicable
-
zxfabqvvst(qiqazjyrcy) = wkupyypfbc rshlcbehgl (rzbttwpnat )
-
01 Nov 2020
zxfabqvvst(qiqazjyrcy) = tdmnwheuyv rshlcbehgl (rzbttwpnat )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free